The Latest Industry News & Insights from Qsight

With the Omicron COVID-19 variant sweeping across the nation, Guidepoint Qsight has gathered insights from physicians on staffing shortages and impact of Omicron at their facility. 46% physicians and administrators in our panel report that their facilities are currently understaffed and are currently hiring. Of the sites that were previously or are currently understaffed, almost…

  After the launch of Penumbra’s new product, the RED 72 catheter, we took a look at its impact and other historical trends in the ischemic stroke market. Qsight’s healthcare facility purchasing dataset shows the immediate impact of recalls and new product launches in the ischemic stroke market. After the recall of the Jet 7…

With Shockwave surpassing Wall Street’s expectations with their third-quarter earnings, Guidepoint Qsight took a closer look at how their new C2 catheter has taken the Coronary Arterial Disease Device market by storm. In February 2021, Shockwave launched its C2 Coronary Intravascular Lithotripsy catheter, which is a device that helps open up calcified arteries to allow…

Guidepoint Qsight’s proprietary Aesthetics data examines patient spending in the United States, providing insight into brand retention in the Neurotoxin space. Using a sample of patients who had at least three Neurotoxin injection visits over at least six months (n=159,657), we reviewed what brand they started on (first visit) and which brand they used in…

Guidepoint Qsight’s unique mix of quantitative healthcare facility purchasing data and qualitative commentary from our Tracker panel uncovers market share, price, and physician sentiment in the U.S. Implantable Cardiac Monitor market. Competitively priced compared to Medtronic’s LINQ and LINQ II, Boston Scientific’s LUX-DX ICM system performed very well after its launch in August 2020, rapidly…

Guidepoint Qsight captured insights into the overall U.S. Orthopedics Knee market, identifying tremendous double-digit growth in Q2 2021, up 13.5% from Q1 2021. Although Zimmer Biomet reported sequential growth (+11.6%) for the U.S. Orthopedic Knee market, Qsight data indicates a loss of share in Q2 2021, marking the second consecutive quarter that Zimmer Knee has…

Guidepoint Qsight’s medical device market-level dataset has captured trends in multiple MedTech market segments. Following the sharp drop at the beginning of the COVID-19 pandemic, U.S. medical device purchasing spend rebounded quickly in July 2020 back to pre-COVID-19 levels for all five market segments captured in our dataset. Segments most subject to elective procedures experienced…

Guidepoint Qsight’s data captured a surge in spending on non-surgical medical aesthetics treatments in March and April 2021. Neurotoxins, dermal fillers, and non-surgical skin tightening reached unprecedented levels in March 2021 with a continued strong growth trend into April, according to Qsight’s aesthetics point-of-sale data. Younger patients are contributing more to the 2021 aesthetic sales…

Guidepoint Qsight is excited to announce the launch of a new Medical Aesthetics market intelligence offering where you can track the latest trends in the U.S. Medical Aesthetics space with insight into several categories, including Neurotoxins, Dermal Fillers, Non-Surgical Fat Reduction, Skin Tightening, Hormone Replacement Therapy, and several more. We’ve used our Medical Aesthetics dataset…

Guidepoint Qsight’s healthcare facilities purchasing dataset provides insight into market share shifts in the neurology space from 2019 to 2020. The dataset includes products used for neuromodulation, pain management, and interventional neurovascular procedures. When looking at medical device purchasing trends, three manufacturers in the space have experienced the largest shifts in market share: Despite a…

Guidepoint Qsight’s healthcare facilities purchasing dataset provides insight into market share shifts in the cardiology space from 2019 to 2020. The dataset includes interventional cardiology (cardiovascular devices, advanced circulatory support devices, heart valve repair/replacement systems), cardiac rhythm management, and electrophysiology segments. Edward’s Lifesciences, Abbott Labs, Medtronic, and Boston Scientific are leading competitors in the interventional…

With COVID-19 continuing to create uncertainty, Guidepoint Qsight has gathered insights from U.S. physicians across healthcare markets on their expected change in procedure volumes at their facility in 2021. Collectively, over half of all physicians believe they will see higher procedure volumes in 2021 than they did in 2020. The Aesthetics market has the highest…